4,893 Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Purchased by Headlands Technologies LLC

Headlands Technologies LLC acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,893 shares of the specialty pharmaceutical company’s stock, valued at approximately $589,000.

Other institutional investors have also bought and sold shares of the company. Rise Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after purchasing an additional 203 shares during the period. Cape Investment Advisory Inc. raised its position in Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock worth $36,000 after acquiring an additional 292 shares in the last quarter. Assetmark Inc. raised its position in Jazz Pharmaceuticals by 37.1% in the fourth quarter. Assetmark Inc. now owns 440 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 119 shares in the last quarter. Newbridge Financial Services Group Inc. raised its position in Jazz Pharmaceuticals by 254.5% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 468 shares of the specialty pharmaceutical company’s stock worth $58,000 after acquiring an additional 336 shares in the last quarter. Finally, V Square Quantitative Management LLC raised its position in Jazz Pharmaceuticals by 63.9% in the fourth quarter. V Square Quantitative Management LLC now owns 680 shares of the specialty pharmaceutical company’s stock worth $84,000 after acquiring an additional 265 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Neena M. Patil sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the transaction, the executive vice president now directly owns 36,629 shares in the company, valued at $4,016,369.85. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 4.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. HC Wainwright reiterated a “buy” rating and issued a $200.00 price target on shares of Jazz Pharmaceuticals in a research report on Friday, May 3rd. Barclays cut their price objective on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Friday, May 3rd. JPMorgan Chase & Co. boosted their price objective on Jazz Pharmaceuticals from $170.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. Finally, Needham & Company LLC cut their price objective on Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating on the stock in a report on Thursday, June 20th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $185.86.

Jazz Pharmaceuticals Stock Up 2.2 %

Shares of NASDAQ JAZZ traded up $2.25 during trading hours on Tuesday, hitting $105.58. The stock had a trading volume of 243,698 shares, compared to its average volume of 682,556. The company has a market capitalization of $6.66 billion, a P/E ratio of 21.31, a P/E/G ratio of 1.62 and a beta of 0.58. The firm’s 50-day moving average price is $107.60 and its two-hundred day moving average price is $115.26. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $146.70. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). The company had revenue of $901.98 million for the quarter, compared to the consensus estimate of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. Analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.